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drugs. For RA, average cost for SC drugs was 24 448€ and it was 30 403€ for the
infusion drugs. For 100 AS patients treated over 2 years, substituting 60% of IV by SC
drugs would generate 353 013€ in savings for the French Statutory health insur-
ance. For RA, such a substitution would yield a 487 977€ saving. Taking into account
transportation costs of 50€ per visit increased respectively the costs associated
with infusion therapies to 31 153€ for AS and 31 085€ for RA. CONCLUSIONS: In the
context of ever-increasing scrutiny over public health care expenditure, differ-
ences in costs should drive the choice of treatment route of administration. Over-
all, replacing current IV Anti-TNF therapies by SC treatments would entail substan-
tial benefits for the French Statutory Health Insurance.
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OBJECTIVES: To estimate the budget impact analysis of Collagenase Clostridium
histolyticum (CCH) vs. fasciectomy (FSC) for the treatment of Dupuytren’s Disease
(DD) in Spain.METHODS: A cost minimization analysis was adopted (effectiveness
was assumed to be equivalent for both techniques). DD related costs were consid-
ered: CCH costs (including drug, administration and visits) were obtained from
clinical trials and a real-life study. FSC costs (including type of admission, visits,
emergency room, re-admissions, tests, drugs and rehabilitation costs) were col-
lected through a retrospective, observational, local study. Unit costs were obtained
from local databases (e-SALUD and BOT). Results were presented from the NHS
perspective for the next 3 years. We assumed 5100 fasciectomies/year (5% annu-
ally) and a 20, 30 and 40% of them will annually utilize CCH. In addition a 10, 15 and
20% of untreated diagnosed patients were expected to receive CCH. All the data
were validated through an expert panel. A sensitivity analysis was performed with
the main variables. RESULTS: The average FSC cost was € 2250 (72% inpatients),
ranging from € 1703 to € 2467 for outpatients and inpatients respectively. The
average CCH cost was € 1220 (1.5 vial/injection and 4 visits) and may drop to € 898
(1.1 vial/injections and 3 visits). The accumulated 3 years BIA was 45,971 € [M€
-2.993, 3.870]. CONCLUSIONS: According to this study, the inclusion of the CCH
produced a 3 years cumulative budgetary impact of € 45,971 [M€ -2.993, 3.870] for
the NHS.
PMS12
BUDGET IMPACT OF GOLIMUMAB IN THE ANTI-TNF TREATMENT OF
RHEUMATOID ARTHRITIS, AKYLOSING SPONDYLITIS AND PSORIATIC
ARTHRITIS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Morais AD, Pereira ML
Janssen Cilag Farmaceutica, São Paulo, Brazil
OBJECTIVES: To estimate the budget impact of adopting golimumab for the treat-
ment of rheumatoid arthritis (RA), akylkosing spondilitis (AS) and psoriatic arthris-
tis (PsA) in the Brazilian public health care system (SUS). METHODS: In Brazil, four
anti-TNF biologics are approved for treatmenting RA, AS and PsA: adalimumab,
etanercept, infliximab, and golimumab. However, only the former three are reim-
bursed in the SUS. Using the public database, DATASUS, the number of patients
receiving anti-TNF treatment for RA, AS and PsA (based on ICD9 codes) was gath-
ered for the last 12 months, along with the associated drug costs. As golimumab is
not yet reimbursed, treatment cost was defined according to law, based on the
mandatory government discount of 21,87% . RESULTS: Around 38.687 patients
received treatment with adalimumab (18.802), etanercept (14.614) and infliximab
(6.840) between March 2011 and February 2012 in the SUS for RA, AS and PsA. In
total, public health care spending with these treatments was about R$
1.005.311.920,00 for the three indications in the same period (average treatment
cost/patient R$ 25.985,78). Assuming the adoption of golimumab in 30% of patients
receiving subcutaneous treatment (adalimumab and etanercept), the budget will
be reduced by about R$ 101 million (11%) in the first year, excluding taxes. These
savings represent over 6.238 new patients/year that can receive treatment with
golimumab for RA, AS, and PsA. The savings can reach up to R$ 303 million /year, if
golimumab is adopted as first choice among subcutaneous anti-TNF treatments.
CONCLUSIONS: With the lowest treatment cost, golimumab has the potential to
reduce public expenditure across all three indications in the SUS. These savings
have important benefits for payers and patients, such as an increase in access to
treatment or investment in other health priorities. Furthermore, with the least
frequent dosing, golimumab presents important advantages in terms of patient
commodity and logistics.
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OBJECTIVES: To estimate the budget impact for the treatment of osteoporosis in
Italy following a treatment pattern with TERIPARATIDE vs. PTH 1-84. METHODS: A
budget impact model was constructed using a decision-tree analysis with a Monte
Carlo technique where a sufficiently large number (currently 500) of individual
patients are processed through the model, saving the result for each patient and
calculating a mean group cost. The model incorporates the vertebral fracture and
non-vertebral fractures odd ratios for TERIPARATIDE vs. PTH 1-84 from the MTC of
Migliore (2012).The odd ratios are held constant for the 18 months of treatment.
The analysis was carried out from the perspective of the Italian health care system
and therefore only direct costs were considered (drug costs and fracture costs).
Vertebral and non-vertebral fracture costs for Italy were taken from Borgstrom
(2011) and inflated to year 2012 using a national inflation index. The average non-
vertebral fracture cost was calculated by adjusting the non-vertebral fracture costs
to the probability of their incidence. The model integrates a univariate sensitivity
analysis and a probabilistic sensitivity analysis. RESULTS: Within 500 Monte Carlo
patient simulations, mean costs per patient were significantly different between
the two alternatives with €11,408 (SD €4,478) and €13,280 (SD €4,643) for the TERIPA-
RATIDE and PTH 1-84 group, respectively (p  0.0001). The robustness of the study
was confirmed through the univariate sensitivity analysis that has shown TERIPA-
RATIDE to remain the cheapest therapeutic option also by decreasing the vertebral
fractures odd ratio of PTH 1-84 up to 50% and through the probabilistic sensitivity
analysis where TERIPARATIDE has shown the highest probability to be the cheap-
est therapeutic option. CONCLUSIONS: Considering the treatment costs and the
costs of the fractures not avoided, TERIPARATIDE is expected to be the cheapest
therapeutic option compared to PTH 1-84.
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OBJECTIVES: Examine the impact of a claims-based severity index for rheumatoid
arthritis (RA) on health care costs and utilizations of RA patients using large U.S.
claims data. METHODS: Adult patients with at least two RA diagnoses and 12
months of continuous health plan enrollment before and after the index date (first
RA diagnosis date) were identified from a large U.S. claims database (10/1/2008 -
09/30/2009). A severity index for rheumatoid arthritis (SIFRA) was developed by
calculating a weighted sum of 34 RA-related indicators including laboratory, clin-
ical and functional status, extra-articular manifestations, surgical history, and
medications as assessed by an expert Delphi panel of six rheumatologists. The
relationship between SIFRA terciles and health care utilizations and costs was also
examined using histograms. A regression model was used to examine the improve-
ment of the model fitting by adding SIFRA. RESULTS: A total of 23,951 RA patients
(mean SIFRA: 9.14) with laboratory information were identified. Descriptive analy-
sis showed that patients in the upper tercile of SIFRA incurred $9,123 more all-
cause health care costs and $1,326 more RA-related health care costs than patients
in the lower tercile of SIFRA. The most dramatic difference between highest and
lowest SIFRA terciles occurred with pharmacy costs ($6,860 vs. $1,919, p0.001).
Health care visits followed a similar to health care costs for SIFRA terciles. Patients
in the highest SIFRA tercile had higher total office visits (110.14 vs. 77.16, p0.001)
and higher RA-related visits (6.72 vs. 3.93, p0.001) compared to patients in the
lowest tercile. Regression results showed that the model was more than 6-times
(611%) superior in explaining the variation in outcomes after adding SIFRA into the
model. CONCLUSIONS: SIFRA demonstrated evidence of being a significant deter-
minant of health care costs and utilizations for RA patients. This study suggests
that SIFRA could be an important methodological tool to control for severity in
RA-related outcomes research.
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OBJECTIVES: Estimate risk-adjusted health care costs and identify associated risk
factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world
data. METHODS: Research-identified data from a system that processes claims for
all Turkish health insurance funds was analyzed. Adult prevalent AS patients with
two AS visits at least 60 days apart, identified between June 1, 2010 and December
31, 2010, were required to have an AS diagnosis before June 1, 2010, with at least 1
year of continuous enrollment for the baseline and follow-up years. Pharmacy,
outpatient and inpatient claims were compiled over the study period for the se-
lected patients. RESULTS: Among 2,383 patients (mean age: 40.52; female: 38%),
51% were age 18-39, 46% were 40-64 years and 3% were age 65 or older. AS diagnoses
were most prevalent in the Marmara region (46%), followed by Aegean (17%), Cen-
tral Anatolia (22%), and Mediterranean (8%). Nearly 40% of AS patients had at least
one cardiovascular, diabetic, respiratory, allergy, Crohn’s disease, uveit and rheu-
matoid arthritis comorbid condition prior to AS diagnosis. 7% of patients were
hospitalized and 46% had at least one outpatient visit during the pre-index period.
Most patients were prescribed non-COX inhibitors (71%) and 35% of patients were
prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients (1%)
had surgery prior to diagnosis. The total annual cost (a4,233) was comprised of
mainly pharmacy (a3,760), followed by outpatient (a297), and inpatient costs (a155),
and an average copay of a21. Prior comorbid conditions including diabetes, respi-
ratory disease as well as hospitalization, glucocorticoid and DMARD use signifi-
cantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey rela-
tive to other European countries, yet, pharmaceutical expenditures cover a signif-
icant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for AS treatment.
A441V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
